In line with the results from the REACH3 trial, the most common adverse event was anemia, which is not surprising taking into account the mechanism of action with JAK inhibition interfering with erythropoietin receptor signaling and the reported safety profile of ruxolitinib [27, 28]. This evidence concerns the gene EPOR and anemia.